Market closed
Eton Pharmaceuticals/$ETON
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Eton Pharmaceuticals
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
Ticker
$ETON
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
30
Website
ETON Metrics
BasicAdvanced
$314M
Market cap
-
P/E ratio
-$0.21
EPS
1.26
Beta
-
Dividend rate
Price and volume
Market cap
$314M
Beta
1.26
52-week high
$12.74
52-week low
$3.03
Average daily volume
256K
Financial strength
Current ratio
1.507
Quick ratio
1.31
Long term debt to equity
0.788
Total debt to equity
27.07
Interest coverage (TTM)
-5.63%
Management effectiveness
Return on assets (TTM)
-9.68%
Return on equity (TTM)
-33.35%
Valuation
Price to revenue (TTM)
9.046
Price to book
19.66
Price to tangible book (TTM)
31.02
Price to free cash flow (TTM)
-585.234
Growth
Revenue change (TTM)
5.64%
Earnings per share change (TTM)
-343.28%
3-year revenue growth (CAGR)
29.90%
3-year earnings per share growth (CAGR)
-21.01%
What the Analysts think about ETON
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Eton Pharmaceuticals stock.
ETON Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ETON Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ETON News
AllArticlesVideos
Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer
GlobeNewsWire·2 weeks ago
Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)
GlobeNewsWire·3 weeks ago
Eton Pharmaceuticals, Inc. (ETON) Q3 2024 Earnings Call Transcript
Seeking Alpha·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Eton Pharmaceuticals stock?
Eton Pharmaceuticals (ETON) has a market cap of $314M as of December 14, 2024.
What is the P/E ratio for Eton Pharmaceuticals stock?
The price to earnings (P/E) ratio for Eton Pharmaceuticals (ETON) stock is 0 as of December 14, 2024.
Does Eton Pharmaceuticals stock pay dividends?
No, Eton Pharmaceuticals (ETON) stock does not pay dividends to its shareholders as of December 14, 2024.
When is the next Eton Pharmaceuticals dividend payment date?
Eton Pharmaceuticals (ETON) stock does not pay dividends to its shareholders.
What is the beta indicator for Eton Pharmaceuticals?
Eton Pharmaceuticals (ETON) has a beta rating of 1.26. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.